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Abstract
Background: Osteosarcoma is the most frequent bone tumor in childhood and adolescence. Patients with primary metastatic
disease have a poor prognosis. It is therefore important to better characterize the biology of this tumor to define new prognostic
markers or therapeutic targets for tailored therapy. Chemokines and their receptors have been shown to be involved in the
development and progression of malignant tumors. They are thought to be active participants in the biology of osteosarcoma.
The function of specific chemokines and their receptors is strongly associated with the biological context and microenvironment
of their expression. In this report we characterized the expression of a series of chemokine receptors in the complex
environment that defines osteosarcoma.
Methods:  The overall level of chemokine receptor mRNA expression was determined using TaqMan RT-PCR of
microdissected archival patient biopsy samples. Expression was then verified at the protein level by immunohistochemistry using
a series of receptor specific antibody reagents to elucidate the cellular association of expression.
Results: Expression at the RNA level was found for most of the tested receptors. CCR1 expression was found on infiltrating
mononuclear and polynuclear giant cells in the tumor. Cells associated with the lining of intratumoral vessels were shown to
express CCR4. Infiltrating mononuclear cells and tumor cells both showed expression of the receptor CCR5, while CCR7 was
predominantly expressed by the mononuclear infiltrate. CCR10 was only very rarely detected in few scattered infiltrating cells.
Conclusion: Our data elucidate for the first time the cellular context of chemokine receptor expression in osteosarcoma. This
is an important issue for better understanding potential chemokine/chemokine receptor function in the complex biologic
processes that underlie the development and progression of osteosarcoma. Our data support the suggested involvement of
chemokines and their receptors in diverse aspects of the biology of osteosarcoma, but also contradict aspects of previous
reports describing the expression of these receptors in this tumor.
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Background
Osteosarcoma is a primary tumor of the bone that
accounts for 5% of childhood cancers and represents the
fifth most frequent tumor in young adults [1]. In 15–20%
of cases metastasis are present at the time of diagnosis. An
additional 20–25% of the patients develop metastasis
during the course of disease and have a very poor progno-
sis despite achievements in multimodal therapy [1]. Cur-
rently osteosarcoma is classified according to histological
criteria with osteoblastic, chondroblastic and fibroblastic
being the most frequent predominant histological ele-
ments [2]. The prognosis for patients is predicted by eval-
uating their response to preoperative chemotherapy
according to the criteria of Salzer-Kuntschik [3]. Addi-
tional markers of tumor characteristics would aid in clas-
sification of the tumor and potentially novel prognostic
markers could be identified to stratify therapy according
to the individual risk.
Chemokines are proinflammatory cytokines that are pro-
duced locally in tissues and function as the directional
cues to sort, direct, and fine tune cell trafficking [4]. The
receptors for chemokines are expressed on a variety of
cells including tumor cells. Their expression on diverse
types of cells associated with tumor progression and the
omnipresence of their ligands has moved them into the
focus of cancer research. Diverse biological roles for
chemokines and their receptors in tumor growth and
metastases have been identified [5-9]. These actions
include: modulation of tumor angiogenesis, tumor sensi-
tivity to apoptosis, tumor proliferation, control of matrix
degradation and the directed invasion of malignant cells
during tumor metastasis [5-9]. Chemokine biology is also
central to the immunologic anti-tumor response through
the recruitment of effector lymphocytes and the subse-
quent regulation of their effector function within tumor
environments [10]. Data from breast carcinoma studies
have suggested that the specific effects mediated through
chemokines could be significantly different depending on
the source of ligand or receptor expression [11]. In a
recent retrospective osteosarcoma patient study, the
mRNA expression of the receptors CXCR4, CCR7 and
CCR10 by osteosarcoma tissue was linked to clinical out-
come [12]. However, the expression and distribution of
some receptors in osteosarcoma is still controversial [13].
Since osteosarcoma consists not only of the tumor cells
derived from a mesenchymal origin, but also of numbers
of infiltrating mononuclear cells [14] we attempted to
define the source of the chemokine receptor expression in
patient samples. Our results show diverse chemokine
receptor expression by different cell types within the
tumor environment.
Methods
Cell lines
Isolation of primary mesenchymal stem cells and the generation of 
clonal immortalized human progenitor cell lines
Primary human CD34- stem cells were isolated from bone
marrow of healthy donors (discarded material from pilot
vials used after local consent) as previously described
[15]. The immune phenotype of the primary and immor-
talized cells was monitored via FACS analysis throughout
the course of experiments as previously described [15].
Osteoblast cell line
The human fetal osteoblast cell line FOB was purchased
from American Type Culture Collection (Manassas, Vir-
ginia, USA). Cells were grown in Ham's F12/Dulbeccos
modified Eagle (Gibco, Karsruhe, Germany) with 2.5 mM
Glutamin, 0.3 mg/ml G418, and 10% FCS at the permis-
sive temperature of 33°C and harvested at 80% conflu-
ency. To induce differentiation the cells were kept at the
restrictive temperature of 39°C for 5–8 days. Cells were
then harvested when no further proliferation could be
observed and analyzed for expression of osteocalcin and
osteopontin using real time RT-PCR Expression levels of
these two genes in undifferentiated osteoblasts were com-
pared with that seen following differentiation (data not
shown). RNA was extracted from all cell lines using the
RNeasy RNA extraction kit (Qiagen, Hilden, Germany)
according to manufacturer's recommendations including
DNAse digestion and followed by transcription (see
below).
Patient samples
Osteosarcoma biopsies
Biopsies were taken from patients with osteosarcoma after
informed consent of the local therapy center and with the
approval of the local ethics committee (ethics committee
of the medical faculty of the Technical University of
Munich) and processed for routine diagnostic procedures.
Discarded material was used for the research purposes
that were carried out in compliance with the Helsinki Dec-
laration. The samples were formaldehyde fixed, paraffin
embedded and archived at room temperature. All sections
of paraffin embedded biopsy tissue were subjected to
microscopic directed manual micro dissection using mor-
phological criteria prior to RNA extraction. A total of 27
samples were analyzed from 27 patients. Morphological
diagnostics revealed osteosarcoma in all cases. Histologi-
cal subtype was determined according to the WHO criteria
[16]. The samples included: 15 osteoblastic sarcoma, one
fibroblastic, four small cell, three chondroblastic, two
teleangetatic, one round cell, and one mixed cell sarco-
mas. Two independent expert pathologists confirmed the
histological diagnosis. RNA was additionally extracted
from one osteoblastoma biopsy as a reference tissue. All
osterosarcoma patients were treated according to theBMC Cancer 2008, 8:23 http://www.biomedcentral.com/1471-2407/8/23
Page 3 of 10
(page number not for citation purposes)
standardized treatment protocol of the German-Austrian-
Swiss OS study group (COSS) active at the time of enrol-
ment (COSS 86, COSS 91 and COSS 96 respectively).
Response to chemotherapy was defined according to the
criteria of Salzer-Kuntschik after tumor resection [3].
Normal bone tissue
Analysis of mature cortical bone was performed on anon-
ymous archival material from the iliac crest obtained
through the Institute of Pathology (LMU).
Tonsil tissue
Analysis of tonsil sections was used to demonstrate posi-
tive controls. Anonymous archival material from
inflamed tonsils was obtained through the Institute of
Pathology (LMU).
RNA extraction method for paraffin embedded 
osteosarcoma tissue
Microdissected specimens from fixed osteosarcoma, bone
tissue sections and tonsil tissue as well as sections from
the osteoblastoma were deparafinized, rehydrated and
harvested in 200 μl lysis buffer containing 2% Sodium
dodecyl sulphate (SDS), 10 mmol/l Tris-HCL (ph 8,0),
0,1 mmol/l ethylenediaminetetraacetic acid (EDTA; ph
8,0), and 500 μg/l proteinase K (Sigma, Steinheim, Ger-
many). Samples were incubated at 60°C for 16 hours.
RNA was extracted using phenol/chloroform extraction.
The pelleted RNA was resuspended in 10/20/30 μl of
RNAse free H2O respectively depending on the amount of
tissue available before RNA extraction.
Because chemokine receptor genes generally contain only
one intron it is often difficult to generate good cDNA spe-
cific real time TaqMan PCR probes (requiring efficient
amplicons of less than 100 nt). To increase flexibility in
probe design, all RNA samples were routinely treated with
DNase I to reduce contamination of genomic DNA prior
to PCR analysis. Twenty-seven Kunitz units of RNAse free
DNAse and 1/10 volume buffer RDD (Qiagen, Hilden,
Germany) were added to each sample. After incubation
for 15 minutes at room temperature, the DNAse was inac-
tivated for 10 minutes at 65°C in presence of 2 mM EDTA.
The entire sample was then reverse transcribed in 20/30/
40 μl volume depending on the amount of RNA, with first
strand buffer, 5 mM DTT (Invitrogen, Scotland), 0,5 mM
dNTP (Amersham Pharmacia, Freiburg, Germany), RNase
inhibitor (RNasin, Promega, Mannheim, Germany) and
0.19 μg/ml Acrylamid (Ambion, Austin TX, USA), 21,5
μg/ml random hexamers (Roche, Mannheim, Germany)
and 172 U reverse transcriptase (Superscript, Invitrogen)
for 1 hour at 42°C.
Real time RT-PCR for quantitative analysis of mRNA 
expression of chemokine receptors
Real time RT-PCR was performed on a TaqMan ABI 7000
Sequence Detection System® (Applied Biosystems, Weiter-
stadt, Germany) using heat activated TaqDNA polymerase
(Amplitaq Gold, Applied Biosystems) essentially as
described [17]. After an initial hold of 2 min at 50°C and
10 min at 95°C the samples were cycled 40 times at 95°C
for 15 sec and 60°C for 60 sec. Quantitative analysis of the
cDNA was done following the ΔCt technique (expression
level = 2CT rRNA – CT gene of interest). CT values indicate the first
cycle with a detectable fluorescence signal in TaqMan RT-
RCR. Gene expression that was negative after 40 cycles in
repeated analysis was determined "not detectable". Very
low positive signals (CT 38–40) were determined as "bor-
derline" values indicating the procedural deviation in this
range of expression where false positive results may occur
and no clear analysis is possible. 18 S rRNA was used for
normalization of cDNA content and amplified in parallel
with the genes of interest. Sample gene expression was
then normalized against rRNA expression levels. No tem-
plate controls (NTC) were negative in all runs. All meas-
urements were performed in duplicates. Commercially
available pre-developed TaqMan reagents were used for
hCCR1, hCCR2, hCCR4, hCCR5, hGAPDH and rRNA
(PDAR). In addition, probes for the following receptors
were generated as described elsewhere: hCCR7, hCXCR4,
hCXCR3, hCXCR5, hCCR10 and hCX3CR1 [15,18,19].
All TaqMan reagents were obtained from Applied Biosys-
tems, Warrington, UK.
Immunohistochemistry
The tissue distribution of chemokine receptors CCR1,
CCR4, CCR7, CXCR3, CXCR5, CCR5, and CCR10 was
determined by immunohistochemistry on consecutive
sections from formalin-fixed paraffin-embedded tissue.
The use of antibodies directed against human CCR5
(MC5, a gift from M. Mack) and CXCR3 (Clone 1C6, BD
Biosciences Pharmingen) were previously described on
fixed tissues [19,20]. Antibodies against CCR10 and CCR4
were a gift from Millennium Pharmaceuticals Inc., (Cam-
bridge, Massachusetts, USA) [15,18,19]. CCR1-specific
antibody reagent was obtained commercially (Santa Cruz
Biotechnology, Santa Cruz, California, USA, sc-6125) and
used as described (Segerer et al. submitted manuscript).
CXCR5-specific antibody was a gift from Elisabeth Krem-
mer (GSF, Munich, Germany). Sections of inflamed
human tonsil were used as positive control material for
the expression of CCR1, CCR5 and CCR7 [20]. Negative
controls were isotype matched IgGs or goat non-immune
serum in case of CCR4 and primary antibody was replaced
by diluent.
The general protocol used for antigen retrieval from archi-
val samples was performed as previously described [19].BMC Cancer 2008, 8:23 http://www.biomedcentral.com/1471-2407/8/23
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In brief, slides were deparafinized in xylene and rehy-
drated in a series of graded ethanol. Slides were treated
with 3% H2O2 to block endogenous peroxide. Antigen
retrieval was performed by autoclaving in Antigen
retrieval solution (Vector Laboratories, Burlingame, CA).
Endogenous biotin was blocked by the Biotin/Avidin
blocking kit (Vector). Primary antibodies were applied for
1 hour, followed by secondary biotinylated antibodies
(Vector) and the ABC reagent (Vector). 3'3' Diaminoben-
zidine (DAB, Sigma, Taufkirchen, Germany) with metal
enhancement (resulting in a black colour product) served
as detection system. Slides were counterstained with
methyl green, dehydrated and mounted. Analysis was per-
formed using Leica DM6000 B microscope with the Leica
software Application Suite AF 6000. A pathologist (R. H.)
analyzed Chemokine receptor expression.
Results
Chemokine receptor mRNA expression in osteosarcoma 
biopsy samples
Following tumor surgery samples are generally fixed in
formalin for diagnostic procedures. The study of gene
expression in fresh tumor samples is often limited by the
availability of snap frozen patient material. In order to
make use of archived tumor material, a method was devel-
oped that allowed efficient extraction of RNA from archi-
val formalin fixed osteosarcoma tumor samples following
manual microdissection of the individual sections (see
Material and Methods and [17]). In these studies TaqMan
RT-PCR analysis was found to be ideally suited for the
mRNA analysis, as it requires relatively small amplicons
thus minimizing the effect of any fragmentation of mRNA
that may have occurred during its extraction from archival
samples.
Twenty-seven paraffin embedded archived specimens of
childhood and adult osteosarcoma from diagnostic biop-
sies were analyzed for expression of chemokine receptor
mRNA. Patient characteristics are summarized in Table 1.
All samples were obtained before therapy, fixed and par-
affin embedded. Unfortunately, not enough mRNA could
be recovered from each sample to analyze all receptors in
parallel. A subgroup of specific chemokine receptors were
selected for detailed study based on mRNA and protein
expression profiles from a series of osteosarcoma cell lines
(data not shown) as well as from literature suggesting the
involvement of specific receptors in cancer, cancer pro-
gression and osteosarcoma [8,12,21,22]. The mRNA
expression levels of CCR1 (n = 21), CCR2 (n = 13), CCR4
(n = 22), CCR5 (n = 12), CCR7 (n = 23), CCR10 (n = 12),
CXCR3 (n = 8), CXCR4 (n = 25), CXCR5 (n = 11) and
CX3CR1 (n = 22) were evaluated using quantitative RT-
PCR (see Materials and Methods).
The expression of specific chemokine receptors in the
osteosarcoma tumor samples was first normalized to
rRNA expression levels (see Figure 1) and then compared
to the expression levels seen in normal bone samples,
undifferentiated and differentiated fetal osteoblasts, pri-
mary mesenchymal stem cells, and an example of benign
bone tumor.
CCR1, CCR2, CCR5, CCR7, CXCR4, CXCR5 and CX3CR1
were found to be expressed in 100% of the osteosarcoma
samples tested. CCR4 was expressed in 21 of 22 samples.
Low but detectable levels of CXCR3 mRNA were detected
in 6 of 8 samples analyzed. Contrary to published reports,
CCR10 mRNA expression was either not detected (signal
was not detected by 40 cycles) (11/12) or was at the bor-
der of delectability (signal detected between cycles 38 and
40) (1/12). Importantly, control MSC and osteoblasts as
well as the osteoblastic tumor sample showed detectable,
and in case of MSC, functional expression of this receptor
[15] (Figure 1). The osteoblastoma sample also showed
expression of CCR1, CCR2, CCR4, CCR5, CCR7, CXCR4,
Table 1: Patient Characteristics
Patient number 27
Age at diagnosis <12 5
13–20 12
21–30 6
31–40 1
41- 3
Sex male 8
female 19
Primary tumor site femur 18
humerus 2
others 7
Outcome DOD 10
CR1 14
CR2 3
Histology osteoblastic 15
small cell 4
chondroblastic 3
teleangetatic 2
round cell 1
fibroblastic 1
mixed 1
Response to chemotherapy good 13
poor 12
unavailable 1*
Relapse yes 11
no 16
Primary metastasis no 21
lung 5
other 1
Survival time <1 year 4
<4 years 4
>4 years 19
* Tumour was removed before onset of chemotherapyBMC Cancer 2008, 8:23 http://www.biomedcentral.com/1471-2407/8/23
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CXCR5 and CX3CR1 at levels similar to those seen in the
osteosarcoma biopsies. Chemokine receptor expression in
mature cortical bone was generally only slightly above the
detection limit (data not shown).
Immunohistochemistry was used to verify the distribution 
of chemokine receptor expression in osteosarcoma 
samples
Chemokine biology is thought to have both positive and
negative effects on tumor growth depending on the bio-
logic context of expression. To better characterize the dis-
tribution of chemokine receptors in osteosarcoma,
immunohistochemistry using receptor specific antibody
reagents was applied. Chemokine receptor expression was
verified on nine representative archived osteosarcoma
biopsies. The receptors analyzed included CCR1, CCR4,
CCR5, CCR7, CCR10, CXCR3, and CXCR5. Antibodies for
the additional receptors were either not available or could
not be used for immunohistochemistry on paraffin
embedded samples. Figure 2 and Fig 3 show representa-
tive osteosarcoma biopsy samples displaying the staining
patterns seen for the various chemokine receptors. HE
staining of the tumor (Figure 2 (G)) shows the histology
of an osteoblastic osteosarcoma with extensive osteoid
mRNA expression analysis of chemokine receptors in osteosarcoma tumor biopsies and bone precursors Figure 1
mRNA expression analysis of chemokine receptors in osteosarcoma tumor biopsies and bone precursors. The 
open black circles indicate values of chemokine receptor expression of mRNA isolates from osteosarcoma biopsy samples 
with each circle representing the value of a single sample. Red Triangles indicate the mRNA expression of the osteoblast-
oma. Median values of at least three independent RNA preparations are represented by green hyphens for primary MSC, 
undifferentiated (orange cross) and differentiated osteoblasts (blue X). The grey field indicates borderline detectable expres-
sion values, defined as CT values between 38 and 40 cycles. All values below are rated as negative values (nd = not detectable). 
The y-axis represents expression levels normalized vs. rRNA. On the x-axis the chemokine receptors are indicated. CCR1, 
CCR2, CCR5, CCR7, CXCR4, CXCR5 and CX3CR1 are expressed in all of the tested samples. CCR4 is expressed in 21/22 
tumors. CXCR3 is only detectable in a fraction of the tested samples and CCR10 is either borderline or not detectable. The 
overall receptor expression is higher in the tumor than in the bone precursors. The benign bone tumor (osteoblastoma) dem-
onstrates expression values that are close to those of the sarcoma tissue.
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Chemokine receptor expression pattern in the cellular context of osteosarcoma Figure 2
Chemokine receptor expression pattern in the cellular context of osteosarcoma. Antigen was retrieved from 
archival fixed sections of osteosarcoma samples. The samples were stained with monoclonal antibodies directed against CD3 
(Becton Dickinson), CCR1, CCR4, CCR5, CCR7, CCR10 and CXCR3. (A) Immunostaining on human tonsil with a monoclonal 
AB directed against CCR5 (×200). (B) IgG2a isotype control for α-CCR5 on human tonsil. (C) Circumscriptive expression of 
CCR5 in a small follicular-like infiltrate (×400). (D) CCR5 staining of sections from human osteosarcoma (×400). Arrows label 
CCR5 positive infiltrating cells in (C) and CCR5 a positive tumor cell in (D) respectively. (E) Scattered expression of CXCR3 
in very few mononuclear infiltrating cells (×400). (F) IgG1 isotype control for α-CXCR3 (×200). (G) HE-staining of a pleomor-
phic osteosarcoma with abundant osteoid production and highly pleomorphic, atypical mononuclear cells (×00). (H) Rare single 
infiltrating cells stain positive for CCR10 (×200).BMC Cancer 2008, 8:23 http://www.biomedcentral.com/1471-2407/8/23
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Chemokine receptor expression pattern in the cellular context of osteosarcoma Figure 3
Chemokine receptor expression pattern in the cellular context of osteosarcoma. (A) Immunostaining on human 
tonsil with a monoclonal AB directed against CCR7 (×200). (B) IgG2a isotype control for α-CCR7 on human tonsil. (C) 
Expression of CCR7 in atypical mononuclear cells and some giant cells between some filigree and arborizing osteoid (×400). 
(D) Goat serum isotype controle for α-CCR4 and α-CCR1 on osteosarcoma sections. (E) and (F) Polynuclear giant cells 
express CCR1 as well as atypical mononuclear cells (E) ×200 and F) ×400). (G) and H) Strong CCR4 expression on cells of the 
inner lining of intratumoral vessels ((G) ×200 and (H) ×400).BMC Cancer 2008, 8:23 http://www.biomedcentral.com/1471-2407/8/23
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production and polymorphic tumor cells. The sections
were stained in parallel for CD3 to distinguish between
infiltrating T cells and tumor cells. All tumor samples
tested showed a scattered infiltration by CD3 positive T-
cells cells (data not shown). Expression of CCR1 was
found in all tumor samples predominantly on polynucle-
ated giant cells of benign origin, but also on a small
number of tumor cells (Fig 3E and 3F). Antibody directed
against CCR4 reproducibly stained the inner lining of
small intratumoral vessels (Fig 3 (G) and 3 (H)). CCR5
was strongly expressed in all analyzed osteosarcoma biop-
sies on tumor cells (Fig 2 (D)) as well as infiltrating T-cells
(Fig 2 (C)). CCR7 expression was demonstrated primarily
on the infiltrating inflammatory cells of each analyzed
sample and in only rare instances on a small subset of
small dismorphic tumor cells (Fig 3 (C)). CXCR3 was
detected on few scattered infiltrating mononuclear cells,
but not on tumor cells, (Fig 2 (E)). The antibody directed
against CCR10 detected only very rare positive infiltrating
cells in one tumor sample (Fig 2 (H)) consistent with the
mRNA data. CXCR5 protein expression could not be
shown in any of the samples (data not shown) even
though CXCR5 mRNA expression could be detected in the
samples (Figure 1). Comparative statistics with regards to
outcome could not be performed, because detectable
expression of most receptors was found in all samples.
Discussion
Osteosarcoma is characterized by a number of complex
cytogenetic abnormalities and biological features, which
have generally not yet been shown to be clinically relevant
as diagnostic or prognostic markers. Further characteriza-
tion of osteosarcoma is needed to aid in therapeutic strat-
egies [2,23]. Chemokine receptors and their ligands have
been implicated in the progression and metastasis of var-
ious tumors [5,7]. CCR7 mRNA expression has recently
been correlated with metastasis free survival in osteosar-
coma patients. CCR7 is known to be expressed by imma-
ture or central memory T cells, B cells and mature
dendritic cells [4]. Interestingly, our data show that CCR7
is expressed primarily on the mononuclear infiltrate asso-
ciated with the tumor and is only very rarely expressed by
the tumor cells. This observation may help explain why
osteosarcoma rarely metastasizes to lymph nodes as CCR7
is associated with leukocyte as well as metastatic tumor
homing to secondary lymphatic organs and supports its
association with the metastasis free survival previously
described [24].
CXCR4 expression has been associated with the aggres-
siveness of osteosarcoma [25]. Unfortunately, CXCR4
specific antibody reagents that worked reproducibly on
archival samples were not available and thus the distribu-
tion of expression could not be established. A recent
report by Oda et al. examining CXCR4 expression in fro-
zen osteosarcoma tumor samples suggests that CXCR4 is
found to be higher expressed on the tumor cells in the
metastatic site as compared to the primary tumor [25]. It
is important to remember that the CXCR4 receptor is
expressed by virtually all leukocytes thus the level of
mRNA expression detected in the primary or metastatic
tumor will be due at least in part to the extent of mononu-
clear infiltration present [4].
Both tumor cells and mononuclear infiltrates were found
to strongly express CCR5. The level of CCR5 expression by
tumor cells did however differ between individual sam-
ples. CCR5 expression has been implicated in tumor pro-
gression [11] and has been linked to angiogenesis [9] but
has not been previously described in osteosarcoma.
Microvessel density in the tumor, representing the level of
neoangiogenesis, has been associated with clinical out-
come in osteosarcoma [26]. The small number of samples
did however not allow the analysis of the correlation
between microvessel density and CCR5 expression. This
association could be of potential therapeutic interest since
CCR5 Antagonists are currently under phase III clinical
evaluation (4).
CCR4 and its ligands (CCL3, CCL17 and CCL22) are
thought to contribute to the formation of vascular struc-
tures by mobilizing smooth muscle precursor cells [27].
CCR4 receptor expression in our samples was localized to
the inner lining of intratumoral vessels by immunohisto-
chemistry. CCR4 has also been previously described on
vascular endothelial cells in brain and heart [28].
Although tumor vessels normally do not show a distinct
smooth muscle layer, CCR4 expression in the osteosar-
coma samples is suggestive of an involvement of this
receptor in neoangiogenesis in this tumor.
The recruitment of leukocytes in acute and chronic
inflammatory processes is in part regulated by CCR1 [4].
While diverse mononuclear cells express CCR1, its expres-
sion has also been described on tumor cells [4,8,29,30].
Here intratumoral polynuclear giant cells predominantly
expressed CCR1 protein. These cells are frequently found
in osteosarcoma and probably represent osteoclasts
derived from macrophages [2]. Their function in the
tumor context is at present unknown. They might contrib-
ute to the recruitment of mononuclear infiltrating cells
into the tumor and thus the anti-tumor response. A poten-
tial link of the number of giant cells and prognosis could
be analyzed given a larger number of samples.
The chemokine receptor CXCR3 is expressed by activated
T cells, NK cells and a subpopulation of monocytes (4). In
the osteosarcoma samples tested, CXCR3 was found
expressed on scattered mononuclear infiltrating cells. The
low number of expressing cells was also reflected in theBMC Cancer 2008, 8:23 http://www.biomedcentral.com/1471-2407/8/23
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low level of mRNA expression detected by TaqMan analy-
sis.
Expression of the CCR10 receptor in osteosarcoma has
been previously associated with clinical parameters [12].
In the study performed here, no significant CCR10 expres-
sion was found at either the mRNA or protein level except
for rare infiltrating mononuclear cells in one patient sam-
ple. However, CCR10 mRNA and protein was easily
detected in the bone derived control cells suggesting that
the reagents were adequate for detection of this receptor
[18]. These results suggest that previously published
reports of an association of CCR10 mRNA expression with
clinical parameters in osteosarcoma patients may have to
be reinterpreted, and emphasizes the importance of veri-
fying mRNA expression using immunohistochemistry
when possible.
The level of chemokine receptor expression was generally
found to be several orders of magnitude higher in the
tumor samples as compared to the levels seen in the con-
trol differentiated and undifferentiated osteoblasts or
MSC. However, the observation that a benign bone tumor
expressed chemokine receptor mRNA at approximately
the same level as malignant tumors suggests that chemok-
ine biology may not be crucial for the transformation of
the bone precursors, but may still play a role in tumor pro-
gression via contribution to neoangiogenesis as well as in
the propagation or spreading of tumor cells. Care should
be taken in the interpretation of the results presented as
differences in the fixation process of human samples or
control tissues could in part influence the results of the
real time PCR analysis. However, the general trend of
chemokine receptor expression is clear. A larger cohort of
osteosarcoma patient samples should allow for more spe-
cific conclusions and the inclusion of potential prognostic
variables.
Conclusion
The results detailed here refine our understanding of the
expression of chemokine receptors in osteosarcoma.
Clearly chemokine receptors may play diverse roles in the
pathology of this tumor. The significance of each receptor
with regards to the course and outcome of the disease
should be evaluated in a larger cohort of patient samples.
Our results emphasize the importance of identifying the
cellular source of the detected chemokine receptor. This is
clearly a central issue when interpreting the significance of
specific findings for the application of prognostic markers
or the characterization of therapeutic targets.
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